COPD Clinical Trial
Official title:
Feasibility of a Multi Component Intervention in Patients With Severe Dyspnea and Obesity
Verified date | October 2022 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Researchers are trying to test the effectiveness and feasibility of a multicomponent lifestyle intervention to support weight loss decreases dyspnea in obese people with chronic lung disease and clinically significant breathlessness.
Status | Completed |
Enrollment | 28 |
Est. completion date | September 30, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria - Age = 18 years. - BMI >=35 - Dyspnea MRC class II or greater - Diagnosis of lung disease - Signed informed consent Exclusion Criteria - BMI <35 - Pregnancy - Recent respiratory illness (within the last 6 weeks) - Recent exacerbation of chronic lung disease (within the last 6 weeks) - Already participating in a structured diet and/or exercise program - Medical contraindication to weight loss (cancer) - Medical contraindication to unsupervised exercise (unstable angina) |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Florida | Jacksonville | Florida |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Breathlessness | Chronic Respiratory Questionnaire Dyspnea | baseline to 12 weeks | |
Secondary | Lean Body Mass (lbs.)using InBody 770 Scale | InBody770 analyzer to define Lean Body Mass (total body weight minus weight of fat). This measure includes organs, skin, bones, water and muscle. | baseline to 12 weeks | |
Secondary | Skeletal Muscle Mass (lbs.) using InBody 770 Scale | InBody770 analyzer to define skeletal muscle mass (total weight of muscle) | baseline to 12 weeks | |
Secondary | Percent Body Fat using InBody 770 Scale | InBody770 analyzer to define percent body fat | baseline to 12 weeks | |
Secondary | Weight using InBody 770 Scale | InBody770 analyzer to define weight | baseline to 12 weeks | |
Secondary | Body Mass Index using InBody 770 Scale | InBody770 analyzer to define Body Mass Index (BMI) is weight in kilograms divided by height in meters squared. A BMI of 25 or below is considered healthy. | baseline to 12 weeks | |
Secondary | Mindful Eating | Mindful Eating Questionnaire- 28 item instrument with a score range of 1-4. Higher scores are associated with lower body mass indexes. | baseline to 12 weeks | |
Secondary | Daily Steps | Number of steps participant takes in a day recorded by Actigraph Activity tracker. | baseline to 12 weeks | |
Secondary | Daily Sedentary Time | Actigraph Activity Tracker to determine the amount of time (minutes) spend sedentary status | baseline to 12 weeks | |
Secondary | Daily Physical Activity | Actigraph Activity Tracker to define the amount of time spent in mild to moderate and vigorous physical activity define by METs | baseline to 12 weeks | |
Secondary | Exercise Capacity | Six-Minute Walking Test | baseline to 12 weeks | |
Secondary | Sleep Time Measures | Actigraph to measure total sleep time | baseline to 12 weeks | |
Secondary | Sleep Efficiency | Time sleeping/ Time reclined | baseline to 12 weeks | |
Secondary | Disease specific quality of life | Chronic Respiratory Questionnaire measures Fatigue , Emotions and Mastery and is a 20 item questionnaire with a range of 1-7. A higher score is best. | baseline to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |